Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company, on 28 October 2019, announced that the completion of a placement of ten million new fully paid ordinary shares in the Company to institutional, professional, and sophisticated investors in Australia and internationally, at a price of A$0.40 per New Share (Institutional Placement). The Institutional Placement will raise A$4.0 million (exclusive of costs).
Kazia Chairman, Iain Ross, commented, "we have been encouraged by a strong interest in the Company from professional and institutional investors, and the Board has considered it appropriate to take the opportunity to strengthen the Company's balance sheet. It is a testament to the Company's growing credibility and prospects that this round has been performed at a premium to our last round, and without the need for warrants, convertible notes, or similar arrangements, and was oversubscribed. The proceeds of the placement will allow us to complete the ongoing phase I clinical study of Cantrixil and the ongoing phase II study of GDC-0084, as well as to make very significant progress in the four collaborative studies of GDC-0084."
A4 Glitter Eva Foam Sheet With Adhesive
Under the terms of the Institutional Placement, 10 million New Shares have been allocated to institutional, professional, and sophisticated investors at a price of A$0.40 per New Share, representing a 14% discount to the last closing price on 23 October 2019 (A$0.465).
New Shares to be issued under the Institutional Placement will be issued without shareholder approval under the Company's existing placement capacity under ASX Listing Rules 7.1 (9,250,000 shares) and 7.1A (750,000 shares). The settlement is expected to occur on or around 31 October 2019 and the New Shares issued under the Institutional Placement are expected to be allotted and commence trading on ASX on 1 November 2019. The New Shares will rank equally with the Company's existing shares on issue.
The Institutional Placement occurs in the context of considerable clinical development activity across both of the Company's oncology assets. Kazia expects to present interim clinical data from its ongoing phase II study of GDC-0084 in glioblastoma at the upcoming Society for Neuro-Oncology (SNO) annual meeting in Phoenix, AZ on 20-24 November 2019. Further data from this and other ongoing studies are anticipated early in calendar 2020.
EVA Foam Sheet, Foam Board, Stickers Glitter, Foam Cla - ToFoam,https://www.defoamy.com/